Subscribe to RSS
DOI: 10.1055/s-0040-1722198
Looking Back on 2020, Looking Forward to 2021
![](https://www.thieme-connect.de/media/10.1055-s-00035024/202101/lookinside/thumbnails/10-1055-s-0040-1722198_200918-1.jpg)
We are embarking on board of 2021 with great expectations as to the ongoing scientific efforts addressing the current clinical emergency globally. In line with previous years, we offer our editorial reflections looking back on 2020, and looking forward to 2021.[1] [2]
Coronavirus disease (COVID-19) has unleashed an unprecedented scientific production, undoubtedly in the best interest of regaining control over the dystopic crisis. The quality of evidence published in major medical journals appeared however to be lower (e.g., according to trial criteria, database) during the first part of 2020 as compared with the same period in 2019, an effect largely due to studies related to COVID-19. A reduction in quality of published evidence represents a major concern, owing to the rapid dissemination and immediate implementation into clinical practice. Even at the highest profile journals in medicine, widely heralded publications (which we avoid to promote through citation here) warranted retraction.
Our Journal has also encountered a major shift in submissions received toward COVID-19-related studies, and a substantial share of COVID-19 publications in 2020.[3] [4] We have nonetheless strived to keep our editorial requirements in mind and thoroughly privileged scientific quality over quantity, as well as international expert guidance.[7] [8] This is reflected by the lower general acceptance rate (under 5%) of manuscripts relating to COVID-19 compared with the overall acceptance rate (around 20%) in the same period. At T&H, we indeed encourage a more traditional and balanced approach to achieve thorough and reliable results for publication.
In 2020, as in previous years,[5] [6] we could once more count on just over 900 submissions from you, a stable number reflecting the trust you place in Thrombosis and Haemostasis. In comparison to others in the field, our Impact factor has maintained a constant trend, specifically reflected by the Percentile index in the hematology and peripheral vascular disease category, which were above 80% over the past 5 years. We continue to serve as a link journal for the European Society of Cardiology Working Groups on Thrombosis and on Atherosclerosis and Vascular Biology, as well as being the official journal of the Society of Thrombosis and Hemostasis Research (GTH), the Spanish (SETH) Society on Thrombosis and Haemostasis, and the Australian Vascular Biology Society (AVBS).
Publication History
Received: 05 December 2020
Accepted: 05 December 2020
Article published online:
21 January 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Lip GYH, Weber C. Thrombosis and Haemostasis Wishes You a Happy New Year Ahead!. Thromb Haemost 2019; 119 (01) 1-2
- 2 Lip GYH, Rigby A, Weber C. A Toast to the Last Decade and a Very Happy 2020 from Thrombosis and Haemostasis!. Thromb Haemost 2020; 120 (01) 1-4
- 3 Weber C, Rigby A, Lip GYH. Thrombosis and Haemostasis 2020 Editor's Choice Papers. Thromb Haemost 2021; 121 (01) 109-114
- 4 Harenberg J, Violi F. Waves of SARS-CoV-2 infection and science in blood coagulation – a link and beyond. Thromb Haemost 2021; 121 (01) 4-6
- 5 Weber C, Lip GYH. Thrombosis and Haemostasis 2018 Editor's Choice Papers. Thromb Haemost 2019; 119 (01) 183-186
- 6 Weber C, Rigby A, Lip GYH. Thrombosis and Haemostasis 2019 Editor's Choice Papers. Thromb Haemost 2020; 120 (01) 184-190
- 7 Gerotziafas GT, Catalano M, Colgan MP. et al; Scientific Reviewer Committee. Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: position paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thromb Haemost 2020; 120 (12) 1597-1628
- 8 Bikdeli B, Madhavan MV, Gupta A. et al; Global COVID-19 Thrombosis Collaborative Group. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb Haemost 2020; 120 (07) 1004-1024
- 9 Lu HS, Schmidt AM, Hegele RA. et al. Reporting sex and sex differences in preclinical studies. Arterioscler Thromb Vasc Biol 2018; 38 (10) e171-e184
- 10 Lu HS, Schmidt AM, Hegele RA. et al. Annual report on sex in preclinical studies: Arteriosclerosis, Thrombosis, and Vascular Biology publications in 2018. Arterioscler Thromb Vasc Biol 2020; 40 (01) e1-e9
- 11 Rigby A, Lip GYH, Weber C. Documenting sex and sex differences in animal studies. Thromb Haemost 2020; 120 (06) 879-882